ArticleFrontiers in veterinary science2025
Whole-genome characterization and phylogenetic analysis of pigeon circovirus in racing pigeons from Heilongjiang, China.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pigeon circovirus (PiCV), a globally distributed pathogen, is associated with immunosuppression and high mortality in racing pigeons. Despite its endemicity in Chinese pigeon populations, molecular epidemiological data on PiCV in Northeast China remain scarce. This study reports the first complete genome sequence of PiCV isolated from racing pigeons in Heilongjiang Province. Through next-generation sequencing (NGS) for whole-genome assembly and systematic PCR-Sanger sequencing for validation, we obtained the complete 2,035-bp genome (designated HLJ2024). Homology analysis revealed nucleotide identities of 72.9-97.7% with other PiCV reference strains; notably, the cap (Capsid) protein of HLJ2024 exhibited a signature mutation (isoleucine [I]-leucine [L]) at residue 222 relative to its closest relative strain TF4/SN/2016, with predicted structural alterations proximal to this site. Phylogenetic analysis indicated that strain HLJ2024 forms an independent clade (GI) and is closely related to strains of clade GII (TF4/SN/2016, QD6/SN/2018). Recombination analysis suggested that HLJ2024 likely arose from recombination between two Chinese parental strains-GF17/GuangDong/2014 (major parent) and TY2/SN/2016 (minor parent). Our findings reveal active PiCV evolution in Northern China driven by point mutations and inter-regional recombination, providing critical insights into viral adaptability and transmission dynamics in Northeast China. These results provide a foundation for molecular epidemiology-based surveillance of PiCV in this understudied region and hold significant implications for developing targeted prevention strategies tailored to locally circulating strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.